{"filings":[{"id":860877,"accession_number":"0001193125-26-257368","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2026-06-04T20:05:17+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kura Oncology stockholders approve 6.5M share increase for equity plan and 2.5M for ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2014 Equity Incentive Plan, increasing authorized shares by 6.5 million.","Stockholders approved amendment to 2015 ESPP, increasing authorized shares by 2.5 million.","Elected three Class III directors: Diane Parks, Mary T. Szela, and Michael J. Vasconcelles, M.D. to terms expiring 2029.","Ratified Ernst & Young as independent auditor for FY2026; 69.4M for, 140.8K against.","Advisory Say-on-Pay approved (48.8M for, 1.1M against); board set future votes every year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40403,"accession_number":"0001193125-26-219422","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2026-05-12T20:10:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.","Net loss $73.3M (Q1 2025: $57.4M); R&D expense $65.3M, SG&A $31.6M on commercialization investments.","Cash $580.8M plus $180M anticipated Kyowa Kirin payments expected to fund ziftomenib program through 2028.","Payer coverage >93% across >12M lives; early adoption includes repeat use, switching from other menin inhibitors.","Multiple 2026 catalysts: EHA updated KOMET-007 data, ASCO darlifarnib/adagrasib data, KOMET-008 preliminary data."],"consensus_eps_estimate":-0.6456,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":18265000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103873,"accession_number":"0001193125-26-092465","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.","Net product revenue $2.1M from KOMZIFTI in first five weeks of commercial sales post Nov 13 FDA approval.","Collaboration revenue $15.2M (Kyowa Kirin milestones); R&D $64.4M, SG&A $39.1M.","Cash and investments $667.2M; plus $180M in anticipated Kyowa Kirin payments expected to fund through KOMET-017 Phase 3 topline (2028).","2026 milestones include updated KOMET-007 data, KOMET-015 enrollment in GIST, and darlifarnib data in KRAS G12C tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103872,"accession_number":"0001193125-26-029705","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2026-01-29T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Kura Oncology amends bylaws to update advance notice, quorum, indemnification provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Updated advance notice: annual meeting date shift threshold extended to >70 days (previously 30) before alternative notice window applies.","Quorum threshold changed from majority of outstanding shares to majority of voting power; default approval changed to majority of votes cast.","Incorporated universal proxy rules (Rule 14a-19); limited shareholder nominations to number of directors to be elected, no substitute nominees.","Enhanced forum selection: Delaware federal courts as backup for state court actions; added exclusive forum for Securities Act claims.","Expanded mandatory indemnification for directors/officers to maximum extent allowed by law; added expense advancement procedures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103871,"accession_number":"0001193125-26-009649","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["$2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).","$195M milestone payment from Kyowa Kirin in Q4 2025; non-cash collaboration revenue $15-17M.","Cash, cash equivalents & short-term investments $667.3M as of Dec 31, 2025.","KOMZIFTI granted full FDA approval in Nov 2025 for R/R NPM1-mutated AML; NCCN Category 2A.","2026 guidance: non-cash collaboration revenue $45-55M; pipeline milestones include Phase 3 trial enrollment."],"consensus_eps_estimate":-0.4946,"consensus_eps_actual":-3.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":67482000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120149,"accession_number":"0001193125-25-304559","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kura Oncology completes first U.S. commercial sale of KOMZIFTI, triggering $135M milestone payment from Kyowa Kirin","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First commercial sale of KOMZIFTI (ziftomenib) completed on December 2, 2025.","Milestone triggers $135M payment from Kyowa Kirin, expected before year-end 2025.","KOMZIFTI received FDA approval on November 13, 2025.","Payment is under the existing collaboration and license agreement with Kyowa Kirin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120148,"accession_number":"0001193125-25-280255","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kura Oncology announces FDA full approval of KOMZIFTI for NPM1-mutated AML","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted full approval of KOMZIFTI (ziftomenib) on November 13, 2025 for R/R NPM1-mutated AML patients with no satisfactory alternative.","KOMZIFTI is the first and only once-daily oral menin inhibitor approved for this indication, with a CR+CRh rate of 21.4% in the KOMET-001 trial.","Median duration of CR+CRh was 5.0 months; median time to first response was 2.7 months; 88% of responders achieved remission within 6 months.","Kura Oncology set a wholesale acquisition cost of $48,500 per month; global collaboration with Kyowa Kirin oversees U.S. and ex-U.S. commercialization.","Boxed Warning for differentiation syndrome included; no Grade 4 or 5 QTc prolongation reported in the pivotal study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120147,"accession_number":"0001193125-25-263491","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.","Collaboration revenue of $20.8M from Kyowa Kirin partnership; no revenue in prior year.","Pro forma cash $609.7M; cash runway into 2027 supports ziftomenib program through KOMET-017 topline.","First patients dosed in KOMET-017 Phase 3 (frontline AML) and FLT3 inhibitor cohort of KOMET-007.","PDUFA target date Nov 30, 2025 for ziftomenib in R/R NPM1-m AML; two oral ASH 2025 abstracts."],"consensus_eps_estimate":-0.8688,"consensus_eps_actual":-2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":50146000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120146,"accession_number":"0001193125-25-249348","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kura Oncology receives $30M milestone from Kyowa Kirin for first patient dosed in Phase 3 ziftomenib trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$30M milestone payment triggered by first patient dosed in KOMET-017 Phase 3 registrational trials.","Trials evaluate ziftomenib in newly diagnosed NPM1-mutated or KMT2A-rearranged AML.","KOMET-017 consists of two global, randomized, double-blind, placebo-controlled Phase 3 studies.","Payment received under Collaboration and License Agreement with Kyowa Kirin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120145,"accession_number":"0001193125-25-241416","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology increases inducement stock option plan by 750,000 shares to 3.25M total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2023 Inducement Option Plan, adding 750,000 shares for total of 3,250,000 shares.","Plan reserved exclusively for nonstatutory stock options to new employees as inducement material to hire.","Amendment approved without stockholder approval per Nasdaq Rule 5635(c)(4).","Plan administered by independent directors or independent compensation committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136717,"accession_number":"0000950170-25-105024","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.","FDA Priority Review for ziftomenib NDA; PDUFA target action date Nov 30, 2025.","Cash, equivalents and investments $630.7M as of June 30; expected to fund operations into 2027, plus Kyowa Kirin funding.","Phase 3 KOMET-017 trials and first KO-2806/FTI data expected in 2H 2025 at ESMO."],"consensus_eps_estimate":-0.4681,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":29396000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136716,"accession_number":"0001193125-25-153393","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Kura Oncology enters co-promotion agreement with Kyowa Kirin for ziftomenib in AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Co-promotion and medical affairs agreement with Kyowa Kirin US for ziftomenib, a menin inhibitor for AML, dated June 27, 2025.","Kyowa Kirin US will co-promote for up to a certain percentage of US details; parties share costs equally.","Kura leads US medical affairs; parties jointly develop health economics and outcomes research strategy.","Term continues until mutual cessation of US commercialization or expiration of Collaboration Agreement term (up to 10 years after first commercial sale).","Agreement automatically terminates with Collaboration Agreement; either party can terminate for uncured material breach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153940,"accession_number":"0001193125-25-142816","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology reports high remission rates with ziftomenib in newly diagnosed AML trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["92% CRc (93% NPM1-m, 89% KMT2A-r) among 71 evaluable patients in KOMET-007 trial.","80% complete remission (84% NPM1-m, 74% KMT2A-r); 71% CR-MRD negativity for NPM1-m.","Median time to MRD negativity 4.7 weeks (NPM1-m) and 4.4 weeks (KMT2A-r).","Safety consistent with prior data; no QTc prolongation or additive myelosuppression at 600 mg.","Phase 3 KOMET-017 studies expected to start in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153939,"accession_number":"0000950170-25-083046","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve Amended 2014 Plan adding 4.75M shares; annual meeting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved Amended 2014 Equity Incentive Plan, increasing authorized shares by 4,750,000.","Elected Helen Collins, M.D., Thomas Malley, and Carol Schafer as Class II directors until 2028.","Ratified Ernst & Young as independent auditor for fiscal year ending December 31, 2025.","Advisory vote on executive compensation approved with 63,155,796 for, 1,522,754 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153938,"accession_number":"0001193125-25-133717","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology's NDA for ziftomenib accepted with Priority Review; Phase 2 shows 23% CR/CRh rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted NDA for ziftomenib in R/R NPM1-m AML; Priority Review set; PDUFA date Nov 30, 2025.","Phase 2 KOMET-001: 23% (21/92) CR/CRh rate; median OS 16.4 months for responders, 3.5 months for non-responders.","63% of evaluable CR/CRh patients achieved MRD-negative; TRAEs led to discontinuation in 3% of patients.","Ziftomenib previously received Breakthrough Therapy, Fast Track, and Orphan Drug designations; co-developed with Kyowa Kirin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153937,"accession_number":"0000950170-25-061836","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q1 net loss $57.4M; NDA submitted for ziftomenib, $45M milestone earned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["NDA for ziftomenib in R/R NPM1-mutant AML submitted March 31, 2025; FDA review period expected Q2 2025.","Earned $45 million milestone from Kyowa Kirin for NDA submission; pro forma cash $703.2M.","Q1 collaboration revenue $14.1M (vs $0 in Q1 2024); R&D expenses $56.0M, up 54% YoY.","Cash, equivalents and short-term investments $658.2M at March 31, 2025; runway into 2027.","First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST; data at ASCO and EHA upcoming."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":14108000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.73,"calibrated_materiality_score":0.73,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172593,"accession_number":"0000950170-25-027706","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology reports Q4 net loss $19.2M; KOMET-001 trial hits primary endpoint; NDA plan Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 collaboration revenue $53.9M (from Kyowa Kirin), R&D $52.3M, net loss $19.2M vs $42.8M YoY.","KOMET-001 achieved primary endpoint with 20-30% CR/CRh rate in R/R NPM1-mutant AML; NDA submission expected Q2 2025.","FDA and EMA aligned on KOMET-017 Phase 3 protocol using MRD-negative CR for potential accelerated U.S. approval; topline 2028.","Cash, equivalents and short-term investments $727.4M as of Dec 31, 2024; sufficient into 2027 with Kyowa funding.","KOMET-007 Phase 1: 91% CR in 1L adverse-risk AML cohort with intensive chemo (7+3) combination."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":53883000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172592,"accession_number":"0001193125-25-020831","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology reports positive Phase 2 KOMET-001 trial of ziftomenib in R/R NPM1-m AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KOMET-001 achieved primary endpoint CR+CRh with statistical significance; benefit-risk profile encouraging.","NDA submission to FDA for ziftomenib in R/R NPM1-m AML on track for Q2 2025.","Plans to initiate two Phase 3 frontline trials (KOMET-017) in 2H 2025 with dual-primary endpoints for potential accelerated and full approval.","Multiple data presentations expected in 2025 across ziftomenib, KO-2806, and tipifarnib programs.","Collaboration with Kyowa Kirin continues for commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172591,"accession_number":"0001193125-25-006197","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Kura Oncology enters lease for new San Diego headquarters, 32,512 sq ft","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease of 32,512 sq ft at 4930 Directors Place, San Diego, for new principal executive offices and R&D.","Term 7 years 8 months, one 5-year extension option; monthly rent ~$183,693 first year, 3% annual increases.","Rent abatement up to $2.4M and tenant improvement allowance up to $6.2M.","Early termination right after 5.5 years with 12 months notice and 8 months rent penalty.","Obligation includes base rent and additional rent for operating expenses, taxes, utilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172590,"accession_number":"0001193125-25-002189","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Kura Oncology CMO Stephen Dale resigns; Mollie Leoni named CMO, Francis Burrows CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Dale, M.D. resigned as CMO effective Jan 2, 2025 due to personal health challenges.","Settlement provides 18 months base salary, 2024 bonus, and extended option exercise through Mar 31, 2026.","Mollie Leoni, M.D. appointed Chief Medical Officer on Jan 2, 2025.","Francis Burrows, Ph.D. appointed Chief Scientific Officer on Jan 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189580,"accession_number":"0001193125-24-283109","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology increases inducement option plan share reserve by 1.9M shares to total 2.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment to 2023 Inducement Option Plan, adding 1,900,000 shares for a new total of 2,500,000 shares reserved.","Awards limited to nonstatutory stock options for new hires as an inducement material to employment.","Plan approved without stockholder approval under Nasdaq Listing Rule 5635(c)(4).","Eligible recipients are individuals not previously employees or directors; plan administered by independent directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189579,"accession_number":"0001193125-24-262641","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Kura Oncology enters $330M upfront collaboration with Kyowa Kirin for ziftomenib; potential milestones up to $1.491B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $330M to Kura; near-term milestones up to $420M including launch of monotherapy R/R setting.","Additional milestones of $513M for hematologic malignancies, plus up to $228M if field expansion option for solid tumors is exercised.","Kyowa Kirin to lead ex-US development/commercialization; Kura leads US with joint profit/cost sharing on US commercialization.","Kura retains rights to next-generation menin inhibitors outside oncology field; exclusivity obligations for both parties.","Tiered double-digit royalties on ex-US sales of ziftomenib on a country-by-country basis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189578,"accession_number":"0000950170-24-123321","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.","Cash, cash equivalents and investments $455.3M as of Sep 30, 2024; runway into 2027.","Topline results from registration-directed ziftomenib trial in R/R NPM1-mutant AML expected early 2025.","Phase 1b expansion study of ziftomenib enrolling at 600 mg; 45 patients enrolled since Aug 2024.","First patient dosed in KO-2806 + adagrasib in KRAS G12C NSCLC; GIST proof-of-concept study planned 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206086,"accession_number":"0001193125-24-220529","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kura Oncology appoints Michael Vasconcelles, M.D. to board and compensation committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed as Class III director with term expiring at 2026 annual meeting.","Annual cash retainer $40,000 for board service plus $7,500 for Compensation Committee.","Granted option to purchase 52,000 shares (3-year vest) and 17,333 shares (1-year cliff).","Eligible for future automatic annual option grants of 26,000 shares.","Standard indemnification agreement; no reportable transactions under Item 404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206085,"accession_number":"0000950170-24-093945","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q2 net loss $50.8M; cash $491.5M; ziftomenib pivotal data expected early 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.8M in Q2 2024 vs $37.2M in Q2 2023; R&D expenses $39.7M vs $28.2M.","Cash, equivalents & short-term investments $491.5M at June 30, 2024; runway into 2027.","Ziftomenib completed enrollment of 85 patients in KOMET-001 pivotal trial; FDA Breakthrough Therapy Designation; topline data early 2025.","Phase 1b expansion of KOMET-007 (ziftomenib + ven/aza and 7+3) now enrolling; data expected Q4 2024.","IND cleared for ziftomenib in GIST; proof-of-concept study with imatinib planned H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223116,"accession_number":"0000950170-24-070584","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kura Oncology stockholders approve 5.5M share increase to equity plan at June 5 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended 2014 Plan, increasing authorized shares by 5.5M to total 29,827,686 shares.","Troy E. Wilson and Faheem Hasnain elected as Class I directors until 2027 annual meeting.","Ratification of Ernst & Young as auditor for FY2024 approved (69.6M for, 56.7K against).","Advisory vote on executive compensation approved with 61.5M for, 5.4M against.","About 69.8M of 76.2M outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223115,"accession_number":"0001193125-24-147030","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kura Oncology completes enrollment of 85 patients in Phase 2 KOMET-001 trial; topline data expected early 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Final enrollment of 85 patients in Phase 2 registration-directed trial of menin inhibitor ziftomenib for NPM1-mutant AML.","Topline data from KOMET-001 trial expected in early 2025.","Trial targets relapsed/refractory NPM1-mutant acute myeloid leukemia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223114,"accession_number":"0000950170-24-052109","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.","FDA granted Breakthrough Therapy Designation to ziftomenib for relapsed/refractory NPM1-mutant AML based on KOMET-001 data.","Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment of 85 patients by mid-2024.","Positive preliminary combo data: 100% CR rate in newly diagnosed with ziftomenib + 7+3; 53% ORR in R/R with venetoclax/azacitidine.","First patient dosed with KO-2806 + cabozantinib in RCC; on track to dose with adagrasib in KRASG12C NSCLC by mid-2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242613,"accession_number":"0000950170-24-021087","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.","Cash and investments $424M at Dec 31, 2023; pro forma $570M after Jan 2024 private placement, runway into 2027.","Enrollment of 85 patients in registration-directed KOMET-001 trial of ziftomenib for NPM1-m AML expected by mid-2024.","Preliminary KOMET-007 data: 100% CR in frontline NPM1-m/KMT2A-r AML with 7+3; 53% ORR in R/R with ven/aza; no differentiation syndrome.","First patient dosed in KOMET-008 (ziftomenib + gilteritinib, FLAG-IDA or LDAC); collaboration with Mirati for KO-2806 + adagrasib."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242612,"accession_number":"0001193125-24-018713","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-01-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Kura Oncology reports $424M cash; ziftomenib combo achieves 100% CR in newly diagnosed AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash $424M as of Dec 31, 2023; net proceeds from private placement $146M.","Phase 1 KOMET-007: 5 newly diagnosed patients on ziftomenib+7+3 all achieved CR (100%).","R/R patients on ziftomenib+ven/aza: ORR 53% (8/15); CR/CRh 56% in menin inhibitor-naïve.","No differentiation syndrome, QTc prolongation, or DLTs observed; well-tolerated.","Expects to complete KOMET-001 enrollment by mid-2024; cash runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242611,"accession_number":"0001193125-24-016715","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Kura Oncology raises $150M via oversubscribed private placement at 29% premium","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$150M gross proceeds from sale of 1.38M shares and 7.32M pre-funded warrants at $17.25/share.","29% premium to Jan 23 close; lead investors include EcoR1 Capital, Deerfield affiliate, Suvretta Capital.","Pro forma cash, equivalents, and investments expected to fund operations into 2027.","Net proceeds to support R&D for clinical-stage candidates and general corporate purposes.","Virtual investor event on Jan 30 to highlight preliminary ziftomenib combination data from KOMET-007."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259996,"accession_number":"0001193125-23-301830","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology adopts 2023 Inducement Option Plan reserving 600,000 shares for new hires","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan reserves 600,000 shares of common stock for nonstatutory stock option grants to new employees as inducement material to employment.","Awards must be approved by a majority of independent directors or independent compensation committee per Nasdaq Rule 5635(c)(4).","Plan terms are substantially similar to the company's stockholder-approved Amended and Restated 2014 Equity Incentive Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259995,"accession_number":"0000950170-23-058157","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q3 net loss $38.6M; cash $452.6M; ziftomenib trial enrollment on track for mid-2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $38.6M vs $35.5M YoY; R&D $29.3M; cash $452.6M provides runway to mid-2026.","Enrollment in KOMET-001 registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete 85 patients by mid-2024.","Preliminary data from 20 patients in KOMET-007 combination trial (ziftomenib + venetoclax/azacitidine or 7+3) expected early Q1 2024.","First patient dosed in FIT-001 trial of next-gen FTI KO-2806; collaboration with Mirati for combo with adagrasib in KRAS G12C-mutated NSCLC.","Brian Powl appointed Chief Commercial Officer in August 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277266,"accession_number":"0001193125-23-227632","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Kura Oncology extends Boston lease to 2031; monthly rent ~$108,900 initially","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease extended 7 yrs; new expiry July 31, 2031.","Minimum rent ~$108,900/mo in first year, 2% annual increases thereafter.","Rent credit of ~$544,500 applied Aug 2023-July 2024.","Tenant improvement allowance up to $827,050."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277265,"accession_number":"0000950170-23-037994","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).","Cash, equivalents & investments $477M at June 30, 2023; includes $93.6M net from June offering; runway to mid-2026.","Ziftomenib in NPM1-mutant AML: CR rate 35% at 600 mg RP2D; registration-directed trial (85 pts) enrollment ahead of projections.","Combination study KOMET-007 (ziftomenib + ven/aza or 7+3) now dosing patients; preliminary data expected Q4 2023 or Q1 2024.","Next-gen FTI KO-2806 Phase 1 FIT-001 trial to begin dosing in H2 2023; tipifarnib+alpelisib in HNSCC at highest planned dose cohort."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295162,"accession_number":"0001193125-23-166858","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology prices $100M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,660,871 common shares at $11.50 and 3,034,782 pre-funded warrants at $11.4999 per warrant.","Expected net proceeds of $93.6M; closing on June 16, 2023.","Underwriters granted 30-day option to buy up to 1,304,347 additional shares.","BofA Securities, Jefferies and SVB Securities are joint bookrunning managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295161,"accession_number":"0001193125-23-164835","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology reports 35% CR rate with ziftomenib in NPM1-mutant AML at EHA 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["7 of 20 NPM1-mutant AML patients at 600 mg RP2D achieved complete remission (CR) with full count recovery.","Median duration of response 8.2 months; median follow-up 8.8 months; 2 patients underwent SCT and remain in remission.","MEN1-M3271 resistance mutation detected in only 1 of 29 patients post-ziftomenib; ziftomenib active against MEN1-T349M.","Phase 2 registration-directed study (85 patients, 62 sites) enrollment outperforming projections; combination studies initiating.","Differentiation syndrome manageable: 15% Grade 1/2, 5% Grade 3; safety profile consistent with underlying disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295160,"accession_number":"0000950170-23-026086","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment increasing share reserve by 4.05M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At May 31 annual meeting, stockholders approved Amended 2014 Plan increasing authorized shares by 4,050,000.","Diane Parks and Mary T. Szela elected as Class III directors until 2026 annual meeting.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 31, 2023.","Advisory vote on executive compensation approved with ~52M for vs ~0.88M against.","Amended 2014 Plan approved with ~46.8M for, ~5.9M against, ~1.4M abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295159,"accession_number":"0000950170-23-020508","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.","Phase 2 registration trial of ziftomenib in NPM1-mutant AML enrollment exceeding initial projections; 85-patient target.","Updated Phase 1 ziftomenib data to be presented at EHA June 2023; 6/20 NPM1-mutant patients achieved CR at RP2D.","FDA cleared IND for KO-2806, a next-generation FTI; FIT-001 Phase 1 trial expected to dose first patients H2 2023.","First combination study KOMET-007 (ziftomenib + standards of care) to dose first patients in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295158,"accession_number":"0001193125-23-105746","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology reports Phase 1 data for ziftomenib: 30% CR, 35% CRc in R/R NPM1-m AML at RP2D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In 20 NPM1-m R/R AML patients at 600mg RP2D: CR rate 30%, composite CR (CRc) 35%, ORR 40%.","Median duration of CRc response 8.2 months; median OS 5.1 months with 8.0 months follow-up.","Safety: 85% had Grade ≥3 TEAEs; differentiation syndrome (any grade) 20%, Grade 3 DS 5%.","Patients heavily pretreated: median 2.5 prior therapies, 60% prior venetoclax, 15% prior SCT.","Registration-directed Phase 2 study of ziftomenib monotherapy in R/R NPM1-m AML now accruing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315734,"accession_number":"0001193125-23-067513","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Kura Oncology says SVB liquidity concern exposure immaterial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kura acknowledges media reports of a possible liquidity concern at Silicon Valley Bank.","Company states its exposure to any SVB liquidity issue is immaterial.","No financial impact or operational disruption expected from the situation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315733,"accession_number":"0000950170-23-004098","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology reports Q4 2022 net loss $33.1M; ziftomenib shows 30% CR rate in NPM1-mutant AML","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $33.1M, full year $135.8M; cash $438M provides runway into Q4 2025.","Ziftomenib Phase 1: 30% CR rate among 20 NPM1-mutant AML patients at 600 mg recommended Phase 2 dose.","Registration-directed trial KOMET-001 dosed multiple patients; 85-patient enrollment target in US and Europe.","FDA cleared IND for KO-2806, next-generation farnesyl transferase inhibitor; Phase 1 trial expected Q3 2023.","Bristol Myers Squibb made $25M strategic equity investment at $18.25/share; appointed member to steering committee."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315732,"accession_number":"0001193125-23-008358","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kura Oncology CCO Kirsten Flowers resigns; separation agreement provides 6 months salary + 2022 bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kirsten Flowers resigns as Chief Commercial Officer effective Jan 27, 2023.","Separation agreement provides 6 months base salary and 2022 annual cash bonus (discretionary).","Flowers agrees to a 6-month non-compete period following separation.","No successor named; search for replacement is ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315731,"accession_number":"0001193125-23-004159","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Kura Oncology reports preliminary cash balance of ~$438M as of Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Preliminary unaudited cash, cash equivalents and short-term investments were approximately $438 million.","Cash balance is subject to completion of financial closing and audit; actual results may differ.","Company updated its corporate presentation materials (Exhibit 99.1), but substantive details not provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334080,"accession_number":"0001193125-22-302283","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kura Oncology reports ziftomenib 30% CR rate at 600 mg in NPM1-mutant AML; FDA agrees on registration-enabling trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b trial at 600 mg showed 30% CR (6/20) in NPM1-mutant AML vs 17% at 200 mg; median duration of response not reached.","FDA Type C meeting confirmed 600 mg as recommended Phase 2 dose; agreement on key registration study design elements.","Phase 2 registration-directed trial expected to dose first patient in Q1 2023; combination studies with venetoclax/FLT3 planned.","Differentiation syndrome observed: 20% in NPM1-mutant patients at 600 mg (only 5% Grade 3); higher in KMT2A-rearranged patients.","No drug-induced QTc prolongation; six discontinuations none treatment-related; ziftomenib well tolerated overall."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334079,"accession_number":"0001193125-22-276906","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kura Oncology reports Phase 1b KOMET-001 data for ziftomenib in R/R AML; 600 mg shows 25% CR/CRh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b at 600 mg (N=12): 25% CR/CRh rate, 33% composite CR (75% MRD-), 42% ORR.","Phase 1a (N=30): 2 DLTs (pneumonitis at 400 mg, differentiation syndrome at 1000 mg); manageable safety.","Differentiation syndrome occurred in 7 Phase 1b patients; severity declined after DS Guidance implementation.","Oral presentation at ASH on Dec 10, 2022, will include preliminary data from 18 additional Phase 1b extension patients.","Ziftomenib is an oral menin-KMT2A inhibitor targeting NPM1m and KMT2Ar relapsed/refractory AML."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334078,"accession_number":"0001193125-22-276373","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Kura Oncology secures $25M equity from BMS and up to $125M debt from Hercules; runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bristol Myers Squibb invests $25M at $18.25/share for 1.37M shares; BMS appoints member to Global Steering Committee.","Hercules Capital provides up to $125M term loan; $10M drawn immediately, $15M available at Kura’s discretion.","Additional $75M in two tranches upon clinical milestones; fourth $25M tranche subject to Hercules approval.","Loan bears 8.65% interest; interest-only for 24 months extendable to 48 months; matures Nov 2027.","Proceeds from both transactions, if fully drawn, extend cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334077,"accession_number":"0000950170-22-021564","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.","Cash, equivalents & short-term investments $427.8M pro forma $462.8M after $25M BMS equity and $10M Hercules draw.","$125M Hercules term loan: $10M drawn immediately, up to $115M additional upon milestones; runway into 2026.","Updated ziftomenib Phase 1 data from KOMET-001 accepted for oral presentation at ASH Dec 10, 2022.","AIM-HN registration trial of tipifarnib in HRAS mutant HNSCC closed to enrollment; KURRENT-LUNG trial initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351491,"accession_number":"0001193125-22-254305","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"KURA Oncology amends equity plan to increase shares by 1.46M and grants PSUs to executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board approved amendment to 2014 Equity Incentive Plan to increase shares by 1,459,800, subject to stockholder approval at 2023 Annual Meeting.","Compensation Committee and Board granted PSUs totaling 1,235,100 shares to five executive officers, contingent on stockholder approval of amendment.","PSU vesting tied to milestones: FDA NDA approval for ziftomenib in AML, initiation of registration-enabling trial, and Phase 2 start of farnesyl transferase inhibitor combination.","Executive officers receiving PSUs: CEO Troy Wilson (547,500), CLO Teresa Bair (146,700), CMO Stephen Dale (247,500), CCO Kirsten Flowers (146,700), COO Kathleen Ford (146,700)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351490,"accession_number":"0000950170-22-014242","cik":1422143,"company_name":"Kura Oncology, Inc.","ticker":"KURA","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.","Cash, cash equivalents and investments total $450.3M as of June 30, 2022, providing runway through 2024.","Recommended Phase 2 dose for ziftomenib identified, pending FDA review; additional 18 patients enrolled in KOMET-001 trial.","Preliminary activity observed in KURRENT-HN trial of tipifarnib + alpelisib; first patient dosed in HRAS overexpression cohort.","KURRENT-LUNG trial of tipifarnib + osimertinib to initiate in Q3; IND for KO-2806 expected by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":893052370.1911913,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-03T23:59:59+00:00|351490"}